ZD6474
Term · Oncology and biomedicine · MLC-T-ONC-009466
A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. ZD6474 blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. ZD6474 is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Caprelsa and vandetanib.
| Identifier | MLC-T-ONC-009466 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | Caprelsa; vandetanib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009466",
"term": "ZD6474",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. ZD6474 blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. ZD6474 is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Caprelsa and vandetanib.",
"expansions": [
"Caprelsa",
"vandetanib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/zd6474/"
}
Record 17,611 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.